E-viri
Recenzirano
Odprti dostop
-
Liu, Kun; Zhu, Youwen; Zhu, Hong; Zeng, Manting
Cancer medicine, March 2024, Letnik: 13, Številka: 5Journal Article
Background Tumor‐treating field (TTFields) was a novel antitumor therapy that provided significant survival for previously treated metastatic non‐small cell lung cancer (mNSCLC). The consistency of the cost of the new treatment regimen with its efficacy was the main objective of the study. Methods The primary parameters, derived from the Phase 3 LUNAR study, were collected to evaluate the cost and efficacy of TTFields plus standard‐of‐care (SOC) (immune checkpoint inhibitors ICIs and docetaxel DTX) or SOC in patients with mNSCLC by establishing a three‐state Markov model over a 15‐year time horizon. Primary outcome measures for this study included costs, life‐years (LYs), quality‐adjusted LYs (QALYs), and incremental cost‐effectiveness ratios (ICERs). Sensitivity analyses were performed. Results The total costs of TTFields plus SOC, TTFields plus ICI, and TTFields plus DTX were $319,358, $338,688, and $298,477, generating 1.23 QALYs, 1.58 QALYs, and 0.89 QALYs, respectively. The ICERs of TTFields plus SOC versus SOC, TTFields plus ICI versus ICI, and TTFields plus DTX versus DTX were $613,379/QALY, $387,542/QALY, and $1,359,559/QALY, respectively. At willingness‐to‐pay (WTP) thresholds of $150,000/QALY, the probability of combination TTFields being cost‐effective was 0%. In addition, TTFields plus SOC exhibited similar efficacy (1.12 QALYs and 1.14 QALYs) and costs ($309,822 and $312,531) in the treatment of squamous cell carcinoma (SCC) and non‐squamous cell carcinoma (NSCC) populations. Conclusions In the United States, TTFields plus SOC as second‐line treatment was not a more cost‐effective strategy for patients with mNSCLC. Of the analyzed regimens, TTFields plus ICI was associated with most significant health benefits. We evaluated the cost‐effectiveness of TTFields plus SOC versus SOC. TTFields plus ICI has the most advantageous health benefits in mNSCLC. TTFields plus SOC is not a more cost‐effectivenss strategy for mNSCLC in the USA.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.